Immuneering's Pancreatic Cancer Drug Shows 64% Survival Rate, Sets Phase 3 Trial
Event summary
- Immuneering reported 64% overall survival at 12 months in a Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, surpassing the standard of care benchmark of 35%.
- The company plans to initiate a pivotal Phase 3 trial (MAPKeeper 301) for first-line metastatic pancreatic cancer in mid-2026, with alignment secured from both the FDA and EMA.
- Immuneering ended 2025 with $217 million in cash, providing runway into 2029.
- The company expects to begin dosing in a Phase 2 trial of atebimetinib + Libtayo® for RAS-mutant non-small cell lung cancer in the second half of 2026.
The big picture
Immuneering's strong Phase 2a trial results position it as a key player in the pancreatic cancer treatment landscape. The strategic alignment with regulatory bodies and a robust cash position set the stage for potential market disruption. The company's focus on Deep Cyclic Inhibitors (DCIs) challenges conventional oncology models, aiming for more durable and tolerable treatments. The upcoming Phase 3 trial and expansion into lung cancer could further solidify its leadership in targeted cancer therapies.
What we're watching
- Clinical Efficacy
- Whether the 64% overall survival rate in the Phase 2a trial can be replicated and sustained in the larger Phase 3 trial.
- Regulatory Approval
- The pace at which Immuneering can secure regulatory approvals for atebimetinib, given the alignment with FDA and EMA.
- Pipeline Expansion
- How Immuneering's expansion into non-small cell lung cancer with Libtayo® will impact its market position and financial performance.
Related topics